Lexicon Pharmaceuticals, Inc. (LXRX) Stock

Lexicon Pharmaceuticals, Inc. (LXRX) is a Healthcare stock trading at $2.01 (as of 2026-06-18), with a market capitalization of $968.35M and a trailing P/E of -28.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Valuation — source: SEC EDGAR (first-party)
Price$2.01
Market Cap$968.35M
P/E Ratio-28.7
EV / EBITDA-37.0
Price / Book4.40
Price / Sales12.82
DCF Value (model)$-2.70
DCF Upside vs Price-234.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$49.80M
Net Margin-101.1%
Return on Equity-12.9%
Debt / Equity0.24
Current Ratio18.79
Revenue Growth (YoY)60.2%
EPS Growth (YoY)-77.8%
FCF Growth (YoY)-62.3%
Financial Health — source: SEC EDGAR
Altman Z-Score-8.75 (distress)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Stock P/E-28.7
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-237.5%
vs Industry-268.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderArtal Group S.A. ($241.39M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMichael S. Exton
Employees103
CountryUS
IPO Date2000-04-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Evolus, Inc. (EOLS)
  • 4D Molecular Therapeutics, Inc. (FDMT)
  • DiaMedica Therapeutics Inc. (DMAC)
  • Akebia Therapeutics, Inc. (AKBA)
  • ProKidney Corp. (PROK)
  • Ocugen, Inc. (OCGN)
  • Kamada Ltd. (KMDA)
  • Lineage Cell Therapeutics, Inc. (LCTX)
LXRX earnings history · LXRX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.